David Thurston – författare
Visar alla böcker från författaren David Thurston. Handla med fri frakt och snabb leverans.
10 produkter
Small-molecule Transcription Factor Inhibitors in Oncology
Av Khondaker Miraz Rahman, David Thurston
Inbunden, 2018
2888 kr
Lägg i varukorg
Oncogenic transcription factors are an increasingly important target for anticancer therapies. Inhibiting these transcription factors could allow tumour cells to be "reprogrammed", leading to apoptosis or differentiation from the malignant phenotype. As the use of kinase inhibitors is gradually …
Small-molecule Transcription Factor Inhibitors in Oncology
Av David Thurston, Khondaker Miraz Rahman
E-bok, 2018
2501 kr
Lägg i varukorg
Oncogenic transcription factors are an increasingly important target for anticancer therapies. Inhibiting these transcription factors could allow tumour cells to be "reprogrammed", leading to apoptosis or differentiation from the malignant phenotype. As the use of kinase inhibitors is gradually …
Cytotoxic Payloads for Antibody–Drug Conjugates
Av David Thurston, Paul J M Jackson
Inbunden, 2019
3357 kr
Lägg i varukorg
Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin …
Cytotoxic Payloads for Antibody-Drug Conjugates
Av Paul J M Jackson, David Thurston
E-bok, 2019
3004 kr
Lägg i varukorg
Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [ i.e ., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin …
Small-molecule Transcription Factor Inhibitors in Oncology
Av David Thurston, Khondaker Miraz Rahman
E-bok, 2018
2501 kr
Lägg i varukorg
Oncogenic transcription factors are an increasingly important target for anticancer therapies. Inhibiting these transcription factors could allow tumour cells to be "reprogrammed", leading to apoptosis or differentiation from the malignant phenotype. As the use of kinase inhibitors is gradually …
Cytotoxic Payloads for Antibody-Drug Conjugates
Av Paul J M Jackson, David Thurston
E-bok, 2019
2939 kr
Lägg i varukorg
Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [ i.e ., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin …
Spiral Staircase
Why I Stepped Off a Rocket Ship to Build a Cathedral
Häftad, 2025
200 kr
Lägg i varukorg
